Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2014 | Recent investigational advances in mantle cell lymphoma treatment

Simon Rule • 5 Dec 2014
ASH 2014
Mantle Cell Lymphoma Lenalidomide
SPRINT

Prof Simon Rule (Derriford Hospital, Plymouth, UK) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses recent advances in the treatment of patients with mantle cell lymphoma (MCL), including the phase 2 SPRINT study of lenalidomide versus investigator’s choice in relapsed or refractory MCL and a phase 2 study of lenalidomide plus rituximab as initial treatment in MCL.

More from Simon Rule

Real-world results in the UK for ibrutinib at first relapsed for MCL 0:48
Real-world results in the UK for ibrutinib at first relapsed for MCL
Simon Rule • 7 Dec 2019
OAsIs trial update: ibrutinib, venetoclax plus obinutuzumab in newly diagnosed MCL 1:30
OAsIs trial update: ibrutinib, venetoclax plus obinutuzumab in newly diagnosed MCL
Simon Rule • 7 Dec 2019
Impressive results for R-BAC post BTKi in R/R MCL 1:28
Impressive results for R-BAC post BTKi in R/R MCL
Simon Rule • 7 Dec 2019
Long-term ibrutinib outcomes vs. prior regimens: pooled analysis in R/R MCL 1:35
Long-term ibrutinib outcomes vs. prior regimens: pooled analysis in R/R MCL
Simon Rule • 6 Dec 2019

Related Videos

First-in-class dual BTK-MALT1 fusion inhibitors for treating resistant mantle cell lymphoma 3:41
First-in-class dual BTK-MALT1 fusion inhibitors for treating resistant mantle cell lymphoma
Vivian Jiang • 7 Dec 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
Mantle cell lymphoma: frontline therapy, the role of autoSCT, the value of MRD, & more 15:05
Mantle cell lymphoma: frontline therapy, the role of autoSCT, the value of MRD, & more
Michael Wang et al. • 27 Sep 2025
The content of VJHemOnc is intended for healthcare professionals